Lead Product(s): CAD-9303
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Cowen Healthcare Investments
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 29, 2020
The Company plans to allocate all proceeds to continue development for its lead cognitive disorder asset, CAD-9303 for the treatment of the cognitive deficits and negative symptoms of schizophrenia.
Lead Product(s): Cad-1883
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2020
The Phase 2 trial is a multicenter, randomized, placebo-controlled study that will evaluate the safety and efficacy of CAD-1883. Efficacy outcome measures.